Login to Your Account



Stimuvax Ekes Out OS Benefit in NSCLC Subgroup

By Catherine Shaffer
Staff Writer

Friday, May 17, 2013
Oncothyreon Inc.'s detailed results for its cancer immunotherapy product L-BLP25 (formerly Stimuvax), reported at the meeting of the American Society of Clinical Oncology Annual Meeting in Chicago, failed to comfort nervous investors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription